|
WEST BERLIN, N.J.--(BUSINESS WIRE)—December 18, 2006--EP
MedSystems, Inc. (NASDAQ: EPMD - News), today announced the launch of its MapMate™
Interface link between its EP-WorkMate® Recording
System and CARTO®
XP Navigation and Ablation System. The CARTO XP System, from Biosense
Webster, is the leading 3D navigation system used in
advanced ablation procedures for treatment of
patients with irregular heartbeats. The MapMate
interface was recently cleared by the FDA for
marketing and distribution in the United States.
The MapMate Interface between EP-WorkMate and CARTO
XP System was designed to simplify procedures by
having the recording system and the three
dimensional navigation system communicate with each
other to combine diagnostic data from each system
and eliminate duplicate demographic data entry.
David Bruce, President and CEO of EP MedSystems commented:
"We are pleased to launch our MapMate Interface,
another new product focused on integrating and
streamlining workflow between the various systems
used in Electrophysiology procedures. It’s available
for new WorkMate system installations and as an
upgrade to our installed base of WorkMate systems.
As a clinical tool it helps simplify procedures, and
as a business opportunity it can increase our
average system revenue and offers upgrade revenue
from our installed base.”
Dr. Koonlawee Nadamanee, MD, FACC, FAHA, Director,
Pacific Rim Electrophysiology Research Institute,
stated,” The MapMate interface fulfills the need for
better integration and communication between the
numerous systems in the EP lab. Being able to
interface electrogram and 3D electroanatomical data
creates workflow efficiencies and is an invaluable
tool during my complex ablations letting me better
focus on the patient and his outcome.”
Currently most labs must separately enter and manage
patient data on their individual recording and
navigation systems. By linking the detailed
electrograms from sites within the heart to the
‘roadmap’ used in conducting ablation procedures,
MapMate Interface allows clinicians to rapidly see
complete information to conduct the proper course of
treatment, and produce comprehensive case reports
from the EP-WorkMate Recording System.
About EP MedSystems:
EP MedSystems develops and
markets cardiac electrophysiology ("EP") products
used to diagnose and treat certain cardiac rhythm
disorders. The Company's EP product line includes
the EP-WorkMate® Electrophysiology Workstation with
RPM(TM) Real-time Position Management(TM) navigation
technology, the EP-4(TM) Computerized Cardiac
Stimulator, fixed and deflectable diagnostic
electrophysiology catheters and related disposable
supplies, the ALERT® System and ALERT family of
internal cardioversion catheters, and the ViewMate®
intracardiac ultrasound catheter imaging system. For
more information, visit our website at
www.epmedsystems.com.
Forward Looking Statements:
This Release may contain
certain statements of a forward-looking nature
relating to future events or the future financial
performance of the Company. Forward-looking
statements include information concerning our
possible or assumed future results of operations and
statements preceded by, followed by or including the
words "believes", "expects", "anticipates",
"intends", "plans", "estimates", "see opportunities"
or similar expressions. Such forward-looking
statements are based on our management's beliefs and
assumptions and on information currently available
to our management. Such forward-looking statements
are only predictions and are subject to risks and
uncertainties that could cause actual results or
events to differ materially and adversely from the
events discussed in the forward-looking statements.
Factors that could cause or contribute to such
differences include, but are not limited to, EP
MedSystems' history of losses, uncertainty of market
acceptance of our products and level of sales,
uncertainty of future profitability and future
liquidity needs, possible costs, fines or penalties
that may be incurred in connection with government
inquiries and investigations and risks regarding
regulatory approvals and demand for new and existing
products, as stated in the Company's Annual Report
filed on Form 10-K and Quarterly Reports filed on
Form 10-Q.
EP MedSystems cautions investors
and others to review the cautionary statements set
forth in this press release and in EP MedSystems'
reports filed with the Securities and Exchange
Commission and cautions that other factors may prove
to be important in affecting the EP MedSystems'
business and results of operations. Readers are
cautioned not to place undue reliance on this press
release and other forward-looking statements, which
speak only as of the date of this release. EP
MedSystems undertakes no obligation to publicly
release the results of any revisions to these
forward-looking statements that may be made to
reflect events or circumstances after the date of
this report or to reflect the occurrence of
unanticipated events.
###
|
